SCHEMBL3147432

SCHEMBL3147432

COC(=O)C1CCCc2cccnc2C1=O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 4/20 0.38
ADORA2A P29274 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
SLC6A15 Q9H2J7 1/20 0.36
PTAFR P25105 2/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CRBN Q96SW2 1/20 0.34
F2 P00734 1/20 0.34
F12 P00748 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
IDH1 O75874 1/20 0.34
HRH1 P35367 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26120675 0.92 P2RX7 (0.39) P2RX7SLC6A15PTAFRALDH1A1TSHR
SCHEMBL30557077 0.92 P2RX7 (0.39) P2RX7SLC6A15PTAFRALDH1A1TSHR
SCHEMBL3312236 0.82 HDAC1 (0.46) P2RX7ADORA2AHDAC1HDAC6ALDH1A1
SCHEMBL30558705 0.82 HDAC1 (0.46) P2RX7ADORA2AHDAC1HDAC6ALDH1A1
SCHEMBL2171208 0.81 P2RX7 (0.37) P2RX7HDAC1HDAC6PTAFRALDH1A1
SCHEMBL2877908 0.78 HRH1 (0.45) SLC6A15ALDH1A1TSHRMEN1KMT2A
SCHEMBL2166539 0.78 NPC1 (0.44) ALDH1A1TSHRMEN1KMT2AIDH1
SCHEMBL27674615 0.75 KDM4E (0.40) P2RX7PTAFRALDH1A1TSHRMEN1
SCHEMBL4875547 0.74 SMN1; SMN2 (0.43) ALDH1A1TSHRIDH1
SCHEMBL14720083 0.74 TBXAS1 (0.47) P2RX7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546410-B2 Heteroaryl-fused macrocyclic pyrimidine derivatives ABBVIE INC. (US) 2013-10-01 US disclosed
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004256-A1 HETEROARYL-FUSED MACROCYCLIC PYRIMIDINE DERIVATIVES CDK2, DPYD, CCNB1 P2RX7 846/4885ADORA2A 189/4885HDAC1 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.